Genomics

Bio & Pharma Genome & Co.’s bile duct cancer drug candidate enters Phase 2 trials

Genome & Company, a South Korean developer of microbiome-based drugs, on Tuesday said its GEN-001, a leading immunotherapy drug candidate for bi...

Bio & Pharma S.Korea's NGeneBio establishes US corporation NGeneBioAI

South Korean medical diagnostic company NGeneBio Co. announced on Monday that it has established an artificial intelligence (AI) precision diagnosti...

Pharamaceuticals Korea’s Genome & Company aims US CMO market

South Korea’s microbiome medicine developer Genome & Company geared up for entering the U.S. market to boost profits and make inroads into...